Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 116 of the 117 references it cites were found in a registry or an index; 11 of the 134 sources its claims cite were checked for support.

Pharmacologic inhibition of somatostatin receptor 2 to restore glucagon counterregulation in diabetes

Open access

Abstract

Glucose homeostasis is primarily maintained by pancreatic hormones, insulin and glucagon, with an emerging role for a third islet hormone, somatostatin, in regulating insulin and glucagon responses. Under healthy conditions, somatostatin secreted from pancreatic islet δ-cells inhibits both insulin and glucagon release through somatostatin receptor- induced cAMP-mediated downregulation and paracrine inhibition of β- and α-cells, respectively. Since glucagon is the body’s most important anti-hypoglycemic hormone, and because glucagon counterregulation to hypoglycemia is lost in diabetes, the study of somatostatin biology has led to new investigational medications now in development that may help to restore glucagon counterregulation in type 1 diabetes. This review highlights the normal regulatory role of pancreatic somatostatin signaling in healthy islet function and how the inhibition of somatostatin receptor signaling in pancreatic α-cells may restore normal glucagon counterregulation in diabetes mellitus.

Overview

CoChat Summary

## TL;DR

This review argues that excessive somatostatin receptor 2 (SSTR2) signaling may suppress counterregulatory glucagon release in type 1 diabetes and advanced type 2 diabetes, contributing to treatment-induced hypoglycemia. It summarizes non-clinical and early clinical evidence that SSTR2 antagonists can restore glucagon responses and reduce hypoglycemia risk.

## Key findings

  • In animal models of T1D, the selective SSTR2 antagonist PRL-2903 normalized plasma glucagon and reduced hypoglycemia burden: in biobreeding rats it “fully alleviated” glucose infusion dependence during clamped hypoglycemia, and in STZ rats it reduced exogenous glucose dependence at low-dose insulin (5 U/kg) but not high-dose insulin (10 U/kg).
  • In recurrently hypoglycemic STZ-T1D rats, PRL-2903 prevented a “20-fold reduction” in the plasma glucagon response after 5 antecedent hypoglycemic episodes in 3 days, raised the glucose nadir from 2.7 mmol/L to 3.7 mmol/L, and reduced time spent in hypoglycemia (≤3.9 mmol/L) by about 50 min.
  • A more potent SSTR2 antagonist, ZT-01, outperformed PRL-2903 in STZ-T1D rats: peak plasma glucagon response was about 4-fold higher than with PRL-2903 during clamped hypoglycemia, and cumulative drug exposure (AUC) was 11 times higher over 24 h.
  • In one phase 1b trial in adults with T1D, ZT-01 (3 or 20 mg) increased peak plasma glucagon by up to 15 pg/mL during level 1 hypoglycemia (3.5 ± 0.3 mmol/L), while placebo showed no response; during level 2 hypoglycemia (2.6 ± 0.2 mmol/L), the increase from baseline to peak glucagon was more than 3-fold higher with ZT-01 than placebo.

## Methods

  • This is a narrative review, not an original experimental study; it compiles prior non-clinical and clinical evidence on SST/SSTR2 biology and SSTR2 antagonism in diabetes.
  • It synthesizes findings from rodent models of T1D, pre-diabetes, and T2D, including STZ-induced diabetes, biobreeding rats, high-fat-fed models, and HFF/low-dose STZ models, plus early human phase 1/1b and phase 2 trial information.
  • Main analyses described in the cited studies include clamped hypoglycemia, bolus insulin challenges, exercise-induced hypoglycemia, oral glucose tolerance tests, pancreas/islet perfusion, and comparisons of glucagon, glucose nadir, and time spent hypoglycemic.

## Limitations

  • The paper states that the human and rodent data are still preliminary in several places; for example, the T2D islet findings “must be confirmed in larger samples,” and the phase 1b ZT-01 trial is described as a manuscript “not yet peer-reviewed.”
  • It notes that only one published abstract had profiled in vivo SSTR2a effects in T2D at the time of writing, so evidence for late-stage T2D remains limited.
  • Evident from the text: because this is a review, it does not present a single unified study design, and the included studies vary in model, dose, route, and hypoglycemia induction method, which the authors themselves say may explain variability in responses.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fphar.2023.1295639

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIGURE 1 The interrelationship among α-, β-, and δ-cells of the endocrine pancreas. The pancreatic islets of Langerhans are composed of three glucose-regulating cell types, α- β- and δ-cells, that secrete glucagon, insulin, and somatostatin (SST), respectively. SST secretion is stimulated by (A) glucagon and (B) β-cells, likely via electrical coupling with δ-cells rather than secreted insulin. (C) SST feeds back to inhibit glucagon and insulin release via SSTR2 in human islets. (D) Glucagon secretion is inhibited by insulin and other β-cell secretory products. SSTR2: somatostatin receptor 2; PP: pancreatic polypeptide.
FIGURE 1 The interrelationship among α-, β-, and δ-cells of the endocrine pancreas. The pancreatic islets of Langerhans are composed of three glucose-regulating cell types, α- β- and δ-cells, that secrete glucagon, insulin, and somatostatin (SST), respectively. SST secretion is stimulated by (A) glucagon and (B) β-cells, likely via electrical coupling with δ-cells rather than secreted insulin. (C) SST feeds back to inhibit glucagon and insulin release via SSTR2 in human islets. (D) Glucagon secretion is inhibited by insulin and other β-cell secretory products. SSTR2: somatostatin receptor 2; PP: pancreatic polypeptide.CC BY · PubMed Central
FIGURE 2 Glucose-dependent secretion of insulin, glucagon and somatostatin (SST) in (A) non-diabetic and diabetic (B) islets. In non-diabetic rodent islets, glucagon secretion is maximally stimulated at low glucose and declines to a nadir at an islet glucose concentration of ∼4–5 mmol/L. SST secretion is low during hypoglycemia and increases as glucose rises above 3 mmol/L. In contrast, in diabetes, counterregulatory glucagon secretion is supressed during hypoglycemia and SST is elevated. The loss of β-cell mass in T1D and late-stage T2D rodent islets results in low insulin secretion, but also increased SST secretion, at least during hypoglycemia, and elevations in glucagon secretion in euglycemia and hyperglycemia. As represented by the dashed green lines, the glucose-dependent secretion of SST in diabetes in not completely understood and different animal models provide conflicting views. More specifically, it is unclear whether SST secretion remains relatively stable (i.e., unresponsive) with increasing glucose concentration, or whether it drops below non-diabetic levels during hyperglycemia in diabetes. Green shaded region indicates the glycemic range over which the majority of counterregulatory glucagon secretion occurs in non-diabetic islets. Inspired by Huising et al. (2018); Noguchi and Huising (2019).
FIGURE 2 Glucose-dependent secretion of insulin, glucagon and somatostatin (SST) in (A) non-diabetic and diabetic (B) islets. In non-diabetic rodent islets, glucagon secretion is maximally stimulated at low glucose and declines to a nadir at an islet glucose concentration of ∼4–5 mmol/L. SST secretion is low during hypoglycemia and increases as glucose rises above 3 mmol/L. In contrast, in diabetes, counterregulatory glucagon secretion is supressed during hypoglycemia and SST is elevated. The loss of β-cell mass in T1D and late-stage T2D rodent islets results in low insulin secretion, but also increased SST secretion, at least during hypoglycemia, and elevations in glucagon secretion in euglycemia and hyperglycemia. As represented by the dashed green lines, the glucose-dependent secretion of SST in diabetes in not completely understood and different animal models provide conflicting views. More specifically, it is unclear whether SST secretion remains relatively stable (i.e., unresponsive) with increasing glucose concentration, or whether it drops below non-diabetic levels during hyperglycemia in diabetes. Green shaded region indicates the glycemic range over which the majority of counterregulatory glucagon secretion occurs in non-diabetic islets. Inspired by Huising et al. (2018); Noguchi and Huising (2019).CC BY · PubMed Central
FIGURE 3 SSTR2 antagonism reverses glucagon counterregulatory failure in T1D and advanced T2D. In non-diabetic conditions, SST secretion decreases and glucagon secretion increases during hypoglycemia (≤3.9 mmol/L) to restore euglycemia. In T1D, counterregulatory glucagon secretion is impaired, possibly due to an increase in inhibitory SST signaling. By blocking SST signaling to the α-cell, pharmacologic SSTR2a improve the glucagon response to insulin-induced hypoglycemia in rodents and humans with T1D and potentially advanced (insulin-deficient) T2D.
FIGURE 3 SSTR2 antagonism reverses glucagon counterregulatory failure in T1D and advanced T2D. In non-diabetic conditions, SST secretion decreases and glucagon secretion increases during hypoglycemia (≤3.9 mmol/L) to restore euglycemia. In T1D, counterregulatory glucagon secretion is impaired, possibly due to an increase in inhibitory SST signaling. By blocking SST signaling to the α-cell, pharmacologic SSTR2a improve the glucagon response to insulin-induced hypoglycemia in rodents and humans with T1D and potentially advanced (insulin-deficient) T2D.CC BY · PubMed Central
FIGURE 4 Fold change in the peak plasma glucagon response to insulin-induced hypoglycemia in rodents pre-treated with SSTR2a versus placebo. Fold change in glucagon represents peak glucagon concentration during level 2 hypoglycemia (<3.0 mmol/L) with SSTR2a divided by peak glucagon concentration with placebo. Rodent models of T1D showed a ∼2.5-fold improvement in peak glucagon response, on average, with SSTR2a versus placebo, whereas animal models with more intact counterregulation (i.e., non-diabetic and pre-T2D) were less responsive to treatment (see text). Clamp: hypoglycemia clamp; Challenge: bolus insulin challenge. STZ: streptozotocin; T1D: type 1 diabetes; BB: biobreeding; MN: microneedle; ND: non-diabetic; Pre-T2D: pre-type 2 diabetic; HFF: high-fat-fed; IP: intraperitoneal; IV: intravenous; SC: subcutaneous.
FIGURE 4 Fold change in the peak plasma glucagon response to insulin-induced hypoglycemia in rodents pre-treated with SSTR2a versus placebo. Fold change in glucagon represents peak glucagon concentration during level 2 hypoglycemia (<3.0 mmol/L) with SSTR2a divided by peak glucagon concentration with placebo. Rodent models of T1D showed a ∼2.5-fold improvement in peak glucagon response, on average, with SSTR2a versus placebo, whereas animal models with more intact counterregulation (i.e., non-diabetic and pre-T2D) were less responsive to treatment (see text). Clamp: hypoglycemia clamp; Challenge: bolus insulin challenge. STZ: streptozotocin; T1D: type 1 diabetes; BB: biobreeding; MN: microneedle; ND: non-diabetic; Pre-T2D: pre-type 2 diabetic; HFF: high-fat-fed; IP: intraperitoneal; IV: intravenous; SC: subcutaneous.CC BY · PubMed Central

Verification

Claims the paper makes

10 Valid · 2 Not valid · 85 Not checked · 27 Own results and interpretations

72 more claims · 6 with their cited sources checked

Create a free account to see all 124 claims and to verify the 123 references still open.

See all claims — free account
  • It may state two separate claims as one. 38
  • Probably not a substantial claim. 16

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 117 references

Cited by

See all 13

Metadata

Authors
Hoffman, E. G., D’Souza, N. C., Liggins, R. T., & Riddell, M. C.
Affiliations
York University (CA)
Corresponding author
Hoffman, Emily G.
Venue
Frontiers in Pharmacology
Published
2024-01-17
Volume
14
Pages
1295639-1295639
ISSN
1663-9812 (ISSN-L)
OpenAlex
W4390940962
Cited by
13
References
117
Citations by year
2026: 6 · 2025: 4 · 2024: 3
FWCI
1.44
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Pharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Juvenile Diabetes Research Foundation Canada
  • Government of Canada
  • Natural Sciences and Engineering Research Council of Canada (261306)
  • Canadian Glycomics Network
  • Breakthrough T1D Canada (2-PAR-2023-1312-A-N)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
somatostatin receptor 2, somatostatin, type 1 diabetes, hypoglycemia, pancreatic islets, alpha cells, pancreatic beta cells, glucose homeostasis, cAMP signaling, islet hormones

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacologic inhibition of somatostatin receptor 2 to restore glucagon counterregulation in diabetes. https://app.cochat.ai/papers/10.3389/fphar.2023.1295639
The paper
Hoffman, E. G., D’Souza, N. C., Liggins, R. T., & Riddell, M. C. (2024). Pharmacologic inhibition of somatostatin receptor 2 to restore glucagon counterregulation in diabetes. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2023.1295639

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.